Drug Profile
Research programme: matrix metalloproteinase-13 inhibitors - Array BioPharma
Latest Information Update: 02 Aug 2019
Price :
$50
*
At a glance
- Originator Array BioPharma
- Class Triazoles
- Mechanism of Action Matrix metalloproteinase 13 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Osteoarthritis
Most Recent Events
- 30 Jul 2019 Array BioPharma has been acquired by Pfizer
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in USA (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Osteoarthritis in USA (PO)